Dr. Neumann

Donna M. Neumann, Ph.D.

Associate Professor

1901 Perdido Street
New Orleans, LA 70112 Phone: 504-568-3179
Fax: 504-568-2361

Lab Website


Dr. Donna Neumann received her PhD in Organic Chemistry in 2004 from the University of New Orleans, New Orleans, LA, where she was a Board of Regents Fellow from 2000-2004. She began her postdoctoral work in 2004 in the research group of Professor James M. Hill in the Department of Ophthalmology at LSUHSC, and received an Individual Ruth L. Kirschstein National Research Service Award for postdoctoral studies (2004-2008). Dr. Donna Neumann joined the department of Pharmacology at LSUHSC in November 2010.


BA Chemistry 2000
University of New Orleans, New Orleans LA

PhD Organic Chemistry 2004
University of New Orleans, New Orleans, LA

Research Interests

Research Interests: Epigenetic Modifications Regulating Ocular HSV-1 Latency and Reactivation  Herpes simplex virus type 1 (HSV-1) is a double-stranded DNA virus that, after the primary infection, enters the sensory neurons of the host and establishes a lifelong latent infection. Neurons harboring latent HSV-1 can reactivate periodically in response to a physical, emotional, or chemical stressor, and once reactivation has been initiated, the virus can replicate in the sensory ganglia, spread back to the periphery, and cause disease, specifically corneal scarring and irreversible blindness. During latency, the HSV-1 genome exists in sensory neurons as a circular episome associated with histones. The molecular mechanisms that govern the HSV-1 maintenance of latency and initiate reactivation of HSV-1 have not yet been well defined, making novel drug discovery for the treatment of recurrent ocular HSV-1 a challenging task. Our research has shown that epigenetic modifications play a critical role in not only the maintenance of HSV-1 latency, but in the reactivation process as well. Our lab has focused on the defining the epigenetic controls regulating HSV-1 latency and reactivation to allow the identification of specific target enzymes or pathways involved in chromatin remodeling associated with HSV-1 infections. Our overall goal is to identify new avenues for the discovery of novel treatments that minimize or eliminate recurrent episodes of ocular HSV-1.   


2010- Women’s Affairs Committee, LSUHSC

Selected Publications

Jursic BS, Upadhyay SK, Creech CC, Neumann DM.* Novel and efficient synthesis and antifungal evaluation of 2,3-functionalized cholestane and androstane derivatives. Bioorg Med Chem Lett 2010;(20):7372-7375. 

Creech CC, Neumann DM.* Changes to euchromatin on LAT and ICP4 are more prevalent following reactivation in rabbits latent with an efficiently reactivating strain of HSV-1. PLoS One 2010;5(11):e15416.

Bhattacharjee PS, Neumann DM, Hill JM. A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits. Curr Eye Res 2009;34:99-102. 

Bhattacharjee PS, Neumann DM, Foster TP, Clement C, Singh G, Thompson H, Kaufman HE, Hill JM. Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model. Invest Ophthalmol Vis Sci 2008;49:4263-4268.

Giordani NV, Neumann DM, Kwiatkowski DL, Bhattacharjee PS, McAnany PK, Hill JM, Bloom DC. During herpes simplex virus type 1 infection of rabbits, the ability to express the latency-associated transcript increases latent-phase transcription of lytic genes. J Virol 2008;82:6056-6060.

Hill JM, Bhattacharjee PS, Neumann DM. Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1corneal disease. Exp Eye Res 2007; 84:801-811.

Neumann DM, Bhattacharjee PS, Hill JM. Sodium butyrate: A chemical inducer of in vivo reactivation of herpes simplex virus type 1 in the ocular mouse model. J Virol 2007; 81:6106-6110.

Neumann DM, Bhattacharjee PS, Giordani NV, Bloom DC, Hill JM. In vivo changes in the patterns of chromatin structure associated with the latent herpes simplex virus type 1 genome in mouse trigeminal ganglia can be detected at early times after butyrate treatment. J Virol 2007; 81:13248-13253